Coverage and coding

As expanding commercial coverage1 makes INTRAROSA a more affordable option for your patients, it’s important to document the diagnosis of moderate to severe dyspareunia due to menopause accurately to facilitate prescription coverage. Use the ICD-10-CM codes below when filing claims to indicate a moderate to severe dyspareunia diagnosis2:
  • N94.10 Unspecified dyspareunia
  • N94.11 Superficial (introital) dyspareunia
  • N94.12 Deep dyspareunia
  • N94.19 Other specified dyspareunia
These codes are preferred over the general dyspareunia CPT code, N94.1, as they provide more specific diagnostic detail for the claim.
Rx Prescription image
See More


INTRAROSA is a steroid indicated for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause.

Important Safety Information

INTRAROSA is contraindicated in women with undiagnosed abnormal genital bleeding.

Estrogen is a metabolite of prasterone. Use of exogenous estrogen is contraindicated in women with a known or suspected history of breast cancer. INTRAROSA has not been studied in women with a history of breast cancer.

In four 12-week randomized, placebo-controlled clinical trials, the most common adverse reaction with an incidence ≥2 percent was vaginal discharge. In one 52-week open-label clinical trial, the most common adverse reactions with an incidence ≥2 percent were vaginal discharge and abnormal Pap smear.

To report SUSPECTED ADVERSE REACTIONS, contact AMAG Pharmaceuticals at 1­-877-411-2510 or FDA at 1-800­-FDA-1088 or

Please see full Prescribing Information.

References: 1. Data on file. AMAG Pharmaceuticals, Inc., Waltham, MA 02451. 2. Dyspareunia. website.
Codes/N00-N99/N80-N98/N94-/N94.1. Updated January 5, 2018. Accessed March 13, 2018.